Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
5.54m
Last Price
$2.48
52-Week Range
$1.72 - $10.6599
03/13/2025 08:00 PM EDT